ASND Form 144: Notice of planned share sale

Ascendis Pharma (ASND) Form 144 filing: the filing dated 03/02/2026 lists a planned sale of ordinary shares through Citigroup Global Markets as broker.

Rhea-AI Filing Summary

Ascendis Pharma (ASND) Form 144 filing: the filing dated 03/02/2026 lists a planned sale of ordinary shares through Citigroup Global Markets as broker. The filing also records a prior disposition of 10,000 ordinary shares on 12/04/2025 with proceeds of 2,081,018.69. The notice notes restricted stock vesting dated 03/02/2026 in connection with compensation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ASND's Form 144 filing report?

It reports a notice of proposed sale of ordinary shares through Citigroup Global Markets. The filing also lists a prior sale of 10,000 shares on 12/04/2025 with proceeds of 2,081,018.69 and restricted stock vesting dated 03/02/2026.

Who is the reporting person on the ASND Form 144?

The filing shows Michael Wolff Jensen as the reporting person. The entry includes a Tuborg Boulevard address and identifies the security as ordinary shares traded on NASDAQ.

Which broker is listed on the Form 144 for ASND?

The broker named is Citigroup Global Markets at 390 Greenwich St, New York. The filing pairs that broker with the Form 144 dated 03/02/2026 for proposed sale activity.

Does the filing disclose previously completed sales of ASND shares?

Yes; it records a completed sale of 10,000 ordinary shares on 12/04/2025 with reported proceeds of 2,081,018.69. That sale is listed under securities sold during the past three months.

Is there restricted stock activity in the ASND filing?

The filing notes restricted stock vesting dated 03/02/2026 tied to compensation for Ascendis Pharma A/S. The entry lists the restricted shares alongside the Form 144 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:52 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001965622
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Ascendis Pharma A/S
SEC File Number	001-36815
Address of Issuer	TUBORG BOULEVARD 12 HELLERUP NETHERLANDS 1105 BP
Phone	45 70 22 22 44
Name of Person for Whose Account the Securities are To Be Sold	JENSEN MICHAEL WOLFF
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EXECUTUVE VP CHIEF LEGAL OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	18349	4442109.00	61977408	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/02/2026	RESTRICTED STOCK VESTING	ASCENDIS PHARMA A/S			18349	03/02/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MICHAEL WOLFF JENSEN TUBORG BOULEVARD 12 HELLERUP G7 DK2900	ORDINARY SHARES	12/04/2025	10000	2081018.69

144: Remarks and Signature

Remarks	SECTION 3 D BASED ON INDICATIVE MARKET PRICE 242.09.SHARES BEING SOLD FOR THE VESTING AND SETTLEMENT OF EQUITY AWARDS. UNDER SECURITIES TO BE SOLD DATE ACQUIRED ARE VARIOUS DATES.THE SALES ARE BEING PERFORMED OVER MULTIPLE DAYS. THESE ARE NON DISCRETIONARY TRANSACTIONS. THESE ARE BEING PERFORMED UNDER AN ESTABLISHED 10B51 PLAN
Date of Notice	03/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/07/2023
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)